Cue Biopharma (CUE) News Today $0.78 -0.02 (-2.68%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CUE Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period LUCID CAPITAL MARKETS Initiates Coverage of Cue Biopharma (CUE) with Buy RecommendationAugust 26 at 8:21 PM | msn.comRecurrent or Metastatic Head and Neck cancer Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and CompaniesAugust 25, 2025 | theglobeandmail.comCue Biopharma initiated with a Buy at Lucid CapitalAugust 25, 2025 | msn.comCue Biopharma to Present Program Updates at Cantor Global Healthcare Conference 2025August 21, 2025 | quiverquant.comQCue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare ConferenceAugust 21, 2025 | globenewswire.comCue Biopharma (NASDAQ:CUE) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPSAugust 15, 2025 | marketbeat.comCue Biopharma announces initiation of investigator sponsored trial of CUE-102August 13, 2025 | msn.comCue Biopharma, Inc.: Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business HighlightsAugust 13, 2025 | finanznachrichten.deCue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma MultiformeAugust 13, 2025 | finance.yahoo.comCue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma MultiformeAugust 13, 2025 | globenewswire.comCue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business HighlightsAugust 12, 2025 | globenewswire.comCue Biopharma (CUE) Expected to Announce Quarterly Earnings on WednesdayAugust 7, 2025 | marketbeat.comCue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck CancerJuly 16, 2025 | globenewswire.comCue Biopharma (NASDAQ:CUE) Trading 0.7% Higher - Here's What HappenedJuly 7, 2025 | marketbeat.comCue Biopharma reports promising results for HPV+ head and neck cancer drug - Investing.comJuly 3, 2025 | investing.comCue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic ... - MorningstarJuly 3, 2025 | morningstar.comMCue Biopharma Amends License Agreement with MIL 40GJuly 1, 2025 | tipranks.comCue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic MalignanciesJuly 1, 2025 | globenewswire.comCue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company’s Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment ...June 26, 2025 | morningstar.comMCue Biopharma Receives FDA Pre-IND Feedback for CUE-401, a Novel Therapeutic Aimed at Autoimmune Diseases - NasdaqJune 26, 2025 | nasdaq.comCue Biopharma Gets Positive FDA Feedback on Trial DesignJune 24, 2025 | marketwatch.comCue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company's Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune DiseaseJune 24, 2025 | globenewswire.comCue Biopharma CFO to ResignJune 10, 2025 | marketwatch.comCue Biopharma, Inc.: Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business HighlightsMay 13, 2025 | finanznachrichten.deCue Biopharma Reports First Quarter 2025 Financial Results and Recent Business HighlightsMay 12, 2025 | globenewswire.comCue Biopharma Inc.May 9, 2025 | marketwatch.comCue Biopharma to Host Virtual Investor Event on May 15, 2025May 8, 2025 | globenewswire.comCue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences ConferenceMay 5, 2025 | globenewswire.comBoehringer, Oxford University and Cumulus to explore brain activity in BPDApril 30, 2025 | msn.comBoehringer and Cue Biopharma to develop autoimmune therapiesApril 16, 2025 | finance.yahoo.comCue in pact with Boehringer for autoimmune and inflammatory diseasesApril 15, 2025 | msn.comCue Biopharma, Inc. (CUE) Business Update Call (Transcript)April 15, 2025 | seekingalpha.comCue Biopharma receives $12M upfront in CUE-501 license pactApril 15, 2025 | markets.businessinsider.comCue Biopharma stock falls after pricing capital raise of $20M via securities offeringApril 15, 2025 | msn.comBoehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseasesApril 15, 2025 | globenewswire.comCue Biopharma Announces Pricing of Approximately $20 Million Public OfferingApril 14, 2025 | globenewswire.comCue Biopharma Announces Proposed Public OfferingApril 14, 2025 | globenewswire.comCue Biopharma to Host Business Update Call and WebcastApril 14, 2025 | globenewswire.comBoehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseasesApril 14, 2025 | globenewswire.comCue Biopharma reports Q4 EPS (13c), consensus (14c)April 2, 2025 | markets.businessinsider.comCue Biopharma Full Year 2024 Earnings: EPS Beats Expectations, Revenues LagApril 2, 2025 | finance.yahoo.comCue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business HighlightsMarch 31, 2025 | globenewswire.comCue Biopharma (CUE) Projected to Post Quarterly Earnings on WednesdayMarch 19, 2025 | marketbeat.comCue Biopharma (NASDAQ:CUE) Stock Price Down 3.8% - What's Next?February 25, 2025 | marketbeat.comCue Biopharma, Inc. (NASDAQ:CUE) Sees Large Growth in Short InterestFebruary 2, 2025 | marketbeat.comArtiva Biotherapeutics appoints new director and committee membersJanuary 29, 2025 | msn.comArtiva expands Board with appointment of Dan Baker, M.DJanuary 29, 2025 | markets.businessinsider.comCue Biopharma, Inc. (NASDAQ:CUE) Short Interest UpdateJanuary 2, 2025 | marketbeat.comCue Biopharma, Inc. (NASDAQ:CUE) CEO Acquires $30,900.00 in StockDecember 19, 2024 | insidertrades.comCue Biopharma, Inc. (NASDAQ:CUE) CEO Purchases $30,900.00 in StockDecember 18, 2024 | marketbeat.com Get Cue Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CUE Media Mentions By Week CUE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CUE News Sentiment▼0.431.03▲Average Medical News Sentiment CUE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CUE Articles This Week▼41▲CUE Articles Average Week Get the Latest News and Ratings for CUE and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Cue Biopharma and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Annexon News Editas Medicine News Humacyte News SOPHiA GENETICS News Adherex Technologies News Tiziana Life Sciences News Aerovate Therapeutics News ProQR Therapeutics News Entrada Therapeutics News Sagimet Biosciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CUE) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cue Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cue Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access